
Anthonius de Boer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6934278/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outâ€ofâ€hospital cardiac arrest and differential risk of cardiac and nonâ€cardiac QTâ€prolonging drugs in 37 000 cases. British Journal of Clinical Pharmacology, 2022, 88, 820-829.	2.4	7
2	Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of out-of-hospital cardiac arrest: real-world data from a population-based study. Europace, 2022, 24, 630-638.	1.7	2
3	Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective. Clinical Pharmacology and Therapeutics, 2022, 112, 344-352.	4.7	24
4	Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis. Journal of Medical Internet Research, 2022, 24, e33446.	4.3	0
5	Influence of allopurinol on thiopurine associated toxicity: A retrospective populationâ€based cohort study. British Journal of Clinical Pharmacology, 2021, 87, 2333-2340.	2.4	4
6	Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes. Scientific Reports, 2021, 11, 2794.	3.3	0
7	Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British Journal of Clinical Pharmacology, 2021, 87, 3508-3517.	2.4	1
8	Statins After Ischemic Stroke in the Oldest. Stroke, 2021, 52, 1244-1252.	2.0	5
9	Sulfonylurea antidiabetics are associated with lower risk of outâ€ofâ€hospital cardiac arrest: Realâ€world data from a populationâ€based study. British Journal of Clinical Pharmacology, 2021, 87, 3588-3598.	2.4	10
10	COVIDâ€19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union. Clinical Pharmacology and Therapeutics, 2021, 109, 1517-1527.	4.7	12
11	Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact. Pharmacoepidemiology and Drug Safety, 2021, 30, 1703-1715.	1.9	11
12	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. European Journal of Cancer, 2021, 158, 234-245.	2.8	12
13	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. Melanoma Research, 2021, 31, 58-66.	1.2	6
14	Opioid use is associated with increased outâ€ofâ€hospital cardiac arrest risk among 40,000â€cases across two countries. British Journal of Clinical Pharmacology, 2021, , .	2.4	2
15	Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 347-355.	3.0	21
16	Statins After Myocardial Infarction in the Oldest: A Cohort Study in the Clinical Practice Research Datalink Database. Journal of the American Geriatrics Society, 2020, 68, 329-336.	2.6	3
17	The development of a test battery to assess the hand–eye functions relevant in predicting easy and accurate tablet subdivision in older people: A pilot study. British Journal of Clinical Pharmacology, 2020, 86, 1969-1981.	2.4	9
18	Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients. British Journal of Clinical Pharmacology, 2020, 86, 763-770.	2.4	2

#	Article	IF	CITATIONS
19	Demographics in the 2020s—Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient care and quality of life. British Journal of Clinical Pharmacology, 2020, 86, 1899-1903.	2.4	8
20	Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. Genes, 2020, 11, 1068.	2.4	2
21	Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1263-1272.	1.9	2
22	COVIDâ€19 vaccines: the importance of transparency and factâ€based education. British Journal of Clinical Pharmacology, 2020, 86, 2107-2110.	2.4	13
23	Association of beta-blockers and first-registered heart rhythm in out-of-hospital cardiac arrest: real-world data from population-based cohorts across two European countries. Europace, 2020, 22, 1206-1215.	1.7	1
24	Developing patient entric medicines for older people: Reflections from the draft EMA paper on the pharmaceutical development of medicines for use in the older population. British Journal of Clinical Pharmacology, 2020, 86, 2008-2013.	2.4	4
25	Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study. Pharmacoepidemiology and Drug Safety, 2020, 30, 1293-1320.	1.9	3
26	Quality of reporting of drug exposure in pharmacoepidemiological studies. Pharmacoepidemiology and Drug Safety, 2020, 29, 1141-1150.	1.9	4
27	Realâ€world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials. International Journal of Cancer, 2020, 147, 3461-3470.	5.1	27
28	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A populationâ€based nested case–control study. British Journal of Clinical Pharmacology, 2020, 86, 1150-1164.	2.4	42
29	The design can limit PRECIS-2 retrospective assessment of the clinical trial explanatory/pragmatic features. Journal of Clinical Epidemiology, 2020, 126, 193-201.	5.0	11
30	Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case–control study. Europace, 2019, 21, 99-105.	1.7	1
31	Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. Pharmacoepidemiology and Drug Safety, 2019, 28, 1563-1571.	1.9	2
32	Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1355-1362.	4.5	27
33	Measuring the impact of pharmacovigilance activities, challenging but important. British Journal of Clinical Pharmacology, 2019, 85, 2235-2237.	2.4	14
34	A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines. Journal of Clinical Epidemiology, 2019, 114, 60-71.	5.0	6
35	Mortality risk in atrial fibrillation: the roleÂof aspirin, vitamin K and non-vitamin K antagonists. International Journal of Clinical Pharmacy, 2019, 41, 1536-1544.	2.1	4
36	Low risk pragmatic trials do not always require participants' informed consent. BMJ: British Medical Journal, 2019, 364, l1092.	2.3	28

#	Article	IF	CITATIONS
37	Cycloâ€oxygenase selectivity and chemical groups of nonsteroidal antiâ€inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase. Fundamental and Clinical Pharmacology, 2019, 33, 589-600.	1.9	5
38	Risk of myocardial infarction associated with nonâ€steroidal antiâ€inflammatory drugs: Impact of additional confounding control for variables collected from selfâ€reported data. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 623-631.	1.5	7
39	Effectiveness and safety of reducedâ€dose fluoropyrimidine therapy in patients carrying the <i>DPYD</i> *2A variant: A matched pair analysis. International Journal of Cancer, 2019, 144, 2347-2354.	5.1	40
40	Effect of <i><scp>CYP</scp>4F2</i> , <i><scp>VKORC</scp>1</i> , and <i><scp>CYP</scp>2C9</i> in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
41	Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. International Journal of Cardiology, 2018, 253, 148-154.	1.7	23
42	Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study. Pediatric Diabetes, 2018, 19, 121-128.	2.9	1
43	Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: longâ€term followâ€up on time trends in the occurrence of cardiovascular disease, risk factors and medications use. British Journal of Clinical Pharmacology, 2018, 84, 776-785.	2.4	31
44	Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. Pharmacoeconomics, 2018, 36, 359-368.	3.3	67
45	Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study. Health and Quality of Life Outcomes, 2018, 16, 222.	2.4	13
46	Commentary on â€~Gender differences in clinical registration trials; is there a real problem?' by Labots <i>et al</i> British Journal of Clinical Pharmacology, 2018, 84, 1639-1640.	2.4	4
47	Effects of age and genetic variations in <i>VKORC1</i> , <i>CYP2C9</i> and <i>CYP3A4</i> on the phenprocoumon dose in pediatric patients. Pharmacogenomics, 2018, 19, 1195-1202.	1.3	2
48	Prescription patterns of angiotensinâ€converting enzyme inhibitors for various indications: A UK populationâ€based study. British Journal of Clinical Pharmacology, 2018, 84, 2365-2372.	2.4	24
49	Combined use of polypill components in patients with type 2 diabetes mellitus. European Journal of Preventive Cardiology, 2018, 25, 1523-1531.	1.8	8
50	The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. BMC Cancer, 2018, 18, 224.	2.6	11
51	Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. Pharmacoepidemiology and Drug Safety, 2017, 26, 285-293.	1.9	18
52	Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. British Journal of Clinical Pharmacology, 2017, 83, 1844-1859.	2.4	17
53	Trends in breast cancer incidence among women with type-2 diabetes in British general practice. Primary Care Diabetes, 2017, 11, 373-382.	1.8	10
54	Defining the noninferiority margin and analysing noninferiority: An overview. British Journal of Clinical Pharmacology, 2017, 83, 1636-1642.	2.4	113

#	Article	IF	CITATIONS
55	The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries. Quality of Life Research, 2017, 26, 2479-2488.	3.1	22
56	Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. British Journal of Cancer, 2017, 116, 1415-1424.	6.4	94
57	Early life antibiotic use and the risk of asthma and asthma exacerbations in children. Pediatric Allergy and Immunology, 2017, 28, 430-437.	2.6	77
58	Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. British Journal of Clinical Pharmacology, 2017, 83, 1835-1843.	2.4	10
59	Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials, 2017, 18, 107.	1.6	56
60	The impact of serum potassiumâ€influencing antihypertensive drugs on the risk of outâ€ofâ€hospital cardiac arrest: A case–control study. British Journal of Clinical Pharmacology, 2017, 83, 2541-2548.	2.4	8
61	Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. Pharmacogenomics, 2017, 18, 1143-1153.	1.3	5
62	Breastfeeding is associated with a decreased risk of childhood asthma exacerbations later in life. Pediatric Allergy and Immunology, 2017, 28, 649-654.	2.6	22
63	The impact of age and sex on the reporting of cough and angioedema with renin–angiotensin system inhibitors: a case/noncase study in VigiBase. Fundamental and Clinical Pharmacology, 2017, 31, 676-684.	1.9	25
64	<i>BRAF</i> Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. Oncologist, 2017, 22, 864-872.	3.7	56
65	Patterns of antiplatelet drug use after a first myocardial infarction during a 10â€year period. British Journal of Clinical Pharmacology, 2017, 83, 632-641.	2.4	7
66	Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and secondâ€generation versus thirdâ€generation oral contraceptives. Pharmacoepidemiology and Drug Safety, 2016, 25, 317-324.	1.9	10
67	Rs895819 in <scp><i>MIR27A</i></scp> improves the predictive value of <scp><i>DPYD</i></scp> variants to identify patients at risk of severe fluoropyrimidineâ€associated toxicity. International Journal of Cancer, 2016, 138, 2752-2761.	5.1	28
68	Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case–control study. British Journal of Clinical Pharmacology, 2016, 81, 370-378.	2.4	18
69	Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study. Pediatric Diabetes, 2016, 17, 433-440.	2.9	6
70	Caseâ€only designs for studying the association of antidepressants and hip or femur fracture. Pharmacoepidemiology and Drug Safety, 2016, 25, 103-113.	1.9	11
71	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics, 2016, 17, 583-591.	1.3	9
72	Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. International Journal of Clinical Pharmacy, 2016, 38, 714-23.	2.1	40

#	Article	IF	CITATIONS
73	Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. Paediatric Drugs, 2016, 18, 251-260.	3.1	33
74	Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. European Respiratory Journal, 2016, 48, 1063-1073.	6.7	89
75	Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. Pharmacoepidemiology and Drug Safety, 2016, 25, 122-131.	1.9	6
76	Organised crime against the academic peer review system. British Journal of Clinical Pharmacology, 2016, 81, 1012-1017.	2.4	20
77	Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled longâ€acting beta2â€agonist use and the risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 2016, 25, 132-141.	1.9	11
78	Digoxin and mortality: lessons for observational studies. British Journal of Clinical Pharmacology, 2016, 81, 4-5.	2.4	2
79	Determinants of angiotensinâ€converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. British Journal of Clinical Pharmacology, 2016, 82, 1647-1659.	2.4	31
80	Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes. Pediatric Pulmonology, 2016, 51, 1113-1121.	2.0	11
81	Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands. Pediatric Diabetes, 2016, 17, 44-52.	2.9	36
82	Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics, 2016, 17, 163-180.	1.3	52
83	Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol. Pharmacoepidemiology and Drug Safety, 2015, 24, 701-708.	1.9	26
84	Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0136324.	2.5	25
85	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. Thrombosis Research, 2015, 136, 69-75.	1.7	28
86	Reduced pre-hospital and in-hospital survival rates after out-of-hospital cardiac arrest of patients with type-2 diabetes mellitus: an observational prospective community-based study. Europace, 2015, 17, 753-760.	1.7	13
87	Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Research, 2015, 17, 100.	5.0	45
88	Increased Mortality by Digoxin in Patients With Atrial Fibrillation?. Journal of the American College of Cardiology, 2015, 65, 220-221.	2.8	0
89	A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. Health Policy, 2015, 119, 195-202.	3.0	29
90	Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. Journal of Clinical Epidemiology, 2015, 68, 122-131.	5.0	221

#	Article	IF	CITATIONS
91	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. Thrombosis Research, 2015, 136, 94-100.	1.7	2
92	Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. Annals of Epidemiology, 2015, 25, 590-596.	1.9	15
93	Chronic comorbidities in children with type 1 diabetes: a population-based cohort study. Archives of Disease in Childhood, 2015, 100, 763-768.	1.9	29
94	Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery. JAMA Surgery, 2015, 150, 1126.	4.3	90
95	Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors. International Journal of Clinical Pharmacy, 2015, 37, 1095-1103.	2.1	16
96	Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema. International Journal of Cardiology, 2015, 201, 644-645.	1.7	6
97	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	13.7	562
98	Essential Medicines Are More Available than Other Medicines around the Globe. PLoS ONE, 2014, 9, e87576.	2.5	85
99	Resting Heart Rate Is a Risk Factor for Mortality in Chronic Obstructive Pulmonary Disease, but Not for Exacerbations or Pneumonia. PLoS ONE, 2014, 9, e105152.	2.5	22
100	Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists. PLoS ONE, 2014, 9, e106072.	2.5	24
101	Quality of drug label information on QT interval prolongation. International Journal of Risk and Safety in Medicine, 2014, 26, 89-98.	0.6	6
102	Population-Based Cohort Study of Anti-Infective Medication Use before and after the Onset of Type 1 Diabetes in Children and Adolescents. Antimicrobial Agents and Chemotherapy, 2014, 58, 4666-4674.	3.2	11
103	Pharmacogenomics of oral antiplatelet drugs. Pharmacogenomics, 2014, 15, 509-528.	1.3	10
104	Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling. Drug Discovery Today, 2014, 19, 1294-1297.	6.4	5
105	Disease History and Medication Use as Risk Factors for the Clinical Manifestation of Type 1 Diabetes in Children and Young Adults: An Explorative Case Control Study. PLoS ONE, 2014, 9, e87408.	2.5	4
106	Use of Oral Glucocorticoids and the Risk of Pulmonary Embolism. Chest, 2013, 143, 1337-1342.	0.8	73
107	Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. European Heart Journal, 2013, 34, 1506-1516.	2.2	47
108	When to publish measures of disproportionality derived from spontaneous reporting databases?. British Journal of Clinical Pharmacology, 2011, 72, 909-911.	2.4	21

#	Article	IF	CITATIONS
109	Nonâ€steroidal antiâ€inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiology and Drug Safety, 2011, 20, 635-642.	1.9	19
110	CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European Heart Journal, 2010, 31, 3046-3053.	2.2	138
111	Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus. Drugs, 2010, 70, 2229-2245.	10.9	47
112	Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiology and Drug Safety, 2008, 17, 1-8.	1.9	37
113	Comparison of different pain scoring systems in critically ill patients in a general ICU. Critical Care, 2008, 12, R15.	5.8	167
114	Comparison of knowledge and accessibility to information sources of HIV/AIDS between blind and sighted populations in Nigeria. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 1093-1097.	1.2	8
115	Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake Inhibitors and Coumarins. Archives of Internal Medicine, 2008, 168, 180.	3.8	127
116	Pharmacogenetics of Glucose-Lowering Drug Treatment. Molecular Diagnosis and Therapy, 2007, 11, 291-302.	3.8	22
117	Rate and determinants of 10-year persistence with antihypertensive drugs. Journal of Hypertension, 2005, 23, 2101-2107.	0.5	162
118	Effectiveness of Interventions by Community Pharmacists to Improve Patient Adherence to Chronic Medication: A Systematic Review. Annals of Pharmacotherapy, 2005, 39, 319-328.	1.9	109